版本:
中国

Seattle Genetics to halt late-stage study of leukemia drug

June 19 U.S. drug developer Seattle Genetics Inc said on Monday it would discontinue a late-stage study of its drug to treat older patients with acute myeloid leukemia due to safety concerns.

The trial data showed a higher rate of deaths in patients who took the drug, vadastuximab talirine, compared to those on a placebo, the company said. (Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by Sai Sachin Ravikumar)

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐